Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Slides:

Advertisements

Similar presentations

J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.

Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.

Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,

Clinical Result Overview

C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.

Post-PCI/MI Thrombotic Events – A Plateletcentric Problem!!!!

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Stents versus Bypass Surgery for Left Main disease Objective:to assess the non-inferiority of stents compared to bypass surgery for unprotected left main.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.

Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.

TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.

Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.

1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.

Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.

Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Discontinuation of medication after nonfatal event: MI

The American College of Cardiology Presented by Dr. Adnan Kastrati

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

Insight into the Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety (GRAVITS) Trial Peter Berger, MD Director, Center for.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Antiplatelet Therapy For STEMI: The Case for Cangrelor

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Dr. Harvey White on behalf of the ACUITY investigators

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Antithrombotics and PAD: A New Paradigm in Practice

Angiography-guided PCI

Antiplatelet Therapy and Secondary Prevention

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

Giuseppe Biondi Zoccai University of Turin, Turin, Italy

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

Five Things You Need to Know About Secondary Prevention Post-ACS

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p < for noninferiority)

(p for noninferiority < 0.001)

on behalf of the ACUITY investigators

What oral antiplatelet therapy would you choose?

(p = for noninferiority)

ARISE Trial Aggressive Reduction of Inflammation Stops Events

47% 50% 21% Event Rate 35 p= # Pts 20 Death 15

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

MATRIX: Radial vs. Femoral

Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Section C: Clinical trial update: Oral antiplatelet therapy

Presentation transcript:

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter, randomized trial. 2 x 2 factorial design. Population:ACS patients (STEMI, NSTEMI, unstable angina with ST depression). Endpoint: Composite of CV death, MI or stroke. Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter, randomized trial. 2 x 2 factorial design. Population:ACS patients (STEMI, NSTEMI, unstable angina with ST depression). Endpoint: Composite of CV death, MI or stroke. CURRENT-OASIS 7

Randomized N=25086 Double dose clopidogrel N=12520 Standard dose clopidogrel N=12566 High dose aspirin N=6253 Low dose aspirin N=6267 High dose aspirin N=6254 Low dose aspirin N=6312 CAG PCI ≤ 72h Double + high N=4298 Double + Low N=4262 Standard + High N=4326 Standard + Low N=4376 No PCI N=7823

p=0.018p<0.001p=0.71p=0.039p=0.009 Event rate at 30 days (%) CURRENT-OASIS 7

p=0.76p=0.35p=0.80p=0.62p=0.22 CURRENT-OASIS 7

Mehta et al. Lancet 2010;376: Conclusion:In patients undergoing PCI for ACS a 7 day double dose clopidogrel regimen was associated with a reduction in CV events and ST. No difference was found between high and low dose aspirin. CURRENT-OASIS 7